The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller

U.S. Panel Backs Approval of Abuse-Resistant Opioid Painkiller

August 7, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

WASHINGTON (Reuters)—A U.S. advisory panel on Thursday recommended approval of Egalet Corp’s long-acting opioid painkiller, Arymo ER (morphine sulfate), saying it dulls pain and could deter abuse by addicts seeking a quick high.

You Might Also Like
  • FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

The panel recommended that the U.S. Food and Drug Administration (FDA) approve the drug and said it deters, but does not eliminate, the risk of abuse if addicts try to snort, chew or inject it.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA is not obliged to follow the recommendations of its advisory committees, but typically does so.

Addicts frequently attempt to increase the speed with which opioids get into their bloodstream by chewing or crushing the pills, or by dissolving and injecting them.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Egalet’s tablets are designed to be extremely hard, making them more difficult to break down to extract the active ingredient. If brought in contact with liquid they turn into a sticky gel difficult to inject with a syringe.

In June, a panel recommended approval of a long-acting, abuse-deterrent opioid made by Pfizer Inc. though it had reservations about the drug’s ability to curb all forms of abuse.

The panel also recommended approval of a long-acting opioid made by Teva Pharmaceutical Industries Ltd. and said it was likely to deter abuse whether addicts sought to swallow, snort or inject it.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The Centers for Disease Control and Prevention estimates that 78 Americans die every day from opioid overdose.

Filed Under: Analgesics, Drug Updates Tagged With: abuse, Addiction, Drugs, FDA, Food and Drug Administration, Opioids

You Might Also Like:
  • FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade
  • Bowing to Pressure, FDA to Reform Painkiller Approval Process

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)